How drug coverage policies affect heart failure treatment
Official title: Impact of Restrictive Drug Coverage Policies on Heart Failure Care
Funded at New York University School of Medicine · NIH-10984164 · Data updated 2026-11-12
This study looks at how strict rules about medication coverage affect patients with heart failure who need important medications, aiming to understand how high costs and extra approval steps make it harder for them to get the treatments they need to stay healthy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 5, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $198,936 |
| NIH project number | 1K23HL171636-01A1 |
| Project ID | NIH-10984164 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with heart failure with reduced ejection fraction who may be affected by restrictive drug coverage policies.
✕Less likely to help
Patients with heart failure who are not affected by drug coverage policies or those who do not require guideline-recommended medications may not benefit from this research.
What this research studies
This research investigates how restrictive drug coverage policies impact the prescription and adherence to life-saving medications for patients with heart failure with reduced ejection fraction (HFrEF). It aims to identify the barriers caused by high out-of-pocket costs and prior authorization requirements that prevent patients from receiving necessary treatments. By analyzing a large database that includes insurance formulary information, electronic health records, and census data, the study will quantify the effects of these policies on medication adherence and health outcomes. The findings could help inform better practices and policies to improve patient care.
Why it matters
Potential benefit: If successful, this research could lead to improved access to essential medications for heart failure patients, potentially reducing preventable deaths.
How similar studies have gone: Previous research has indicated that restrictive drug coverage policies negatively impact medication adherence and patient outcomes, suggesting that this study's approach is grounded in established findings.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Mukhopadhyay, Amrita — New York University School of Medicine
- Study coordinator: Mukhopadhyay, Amrita
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.